Jain Rita 4

What Happened

• Rita Jain, a director of Celldex Therapeutics (CLDX), received a grant of derivative securities: options covering 26,000 shares. The Form 4 reports the acquisition price as $0.00 (no cash exchanged at grant); this reflects an option award, not an immediate stock purchase or sale.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (timely within the SEC 2-business-day rule).
• Security: Derivative (option) for 26,000 shares; reported acquisition price $0.00.
• Footnote: Grant made under Celldex’s 2021 Omnibus Equity Incentive Plan.
• Exercise/strike price, vesting schedule, and post-transaction total holdings were not disclosed in the provided filing.

Context

• This was an option grant (compensation), meaning Jain has the right to acquire shares in the future at terms defined by the option (exercise price and vesting), which were not detailed in the filing. Option grants to directors are common as non-cash compensation and do not indicate an immediate purchase or sale of stock.